IP Library Granted Patent US 8,208,189
Granted Patent B2
US 8,208,189 · App. 12/102,739 · Granted Jun 26, 2012

Treatment of alopecia by micropore delivery of stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,208,189
App. No.
12/102,739
Granted
Jun 26, 2012
Kind
B2
Abstract

A method of restoring hair to skin that has suffered hair loss includes optically ablating an array of spaced-apart microchannels or voids into the skin and transplanting into the voids stem cells, a scaffold and a differentiation factor for causing the stem cells to differentiate into hair follicles.

Claims (21)

1. An apparatus comprising:

a handpiece movable over skin, the handpiece arranged to receive an optical beam having an absorption coefficient in water of about 100 cm −1 to 12,300 cm −1 , the handpiece configured to focus the optical beam at a plurality of spaced-apart locations on the skin with a pulse energy per location of 5 mJ to 40 mJ thereby creating a plurality of voids in the skin for the deposition of a composition,

wherein the composition comprises a stem cell and a growth media, and the handpiece is configured to focus the optical beam to create voids with a depth of about 200 μm to 4 mm, with a density of 200 to 4000 voids per cm 2 per pass, at a rate of 100 per second to 5000 per second, and such that viable tissue separating adjacent voids has a width, at a narrowest point thereof, between about 50 μm and 500 μm.

2. The apparatus of claim 1 , further comprising an applicator arranged to deposit the composition in the voids following the formation of the voids.

3. The apparatus of claim 2 , wherein the applicator further comprises a removable tip that attaches to the handpiece.

4. The apparatus of claim 1 , wherein the composition further comprises a scaffold.

5. The method of claim 4 , wherein the scaffold is selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), fibronectin, collagen 1, and collagen 3.

6. The apparatus of claim 1 , wherein the stem cell is hair follicle cell.

7. The apparatus of claim 6 , wherein the composition further comprises a melanocyte stem cell.

8. The apparatus of claim 1 , wherein the media comprises a proliferation-inducing growth factor.

9. The apparatus of claim 8 , wherein the growth factor is selected from the group consisting of epidermal growth factor (EGF), amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor (bFGF or FGF-2), and transforming growth factor alpha (TGFα), or combinations thereof.

10. The apparatus of claim 1 , wherein the composition further comprises a hair-follicle differentiation factor.

11. The apparatus of claim 10 , wherein the differentiation factor is selected from the group consisting of FGF2, FGF4, noggin, platelet-derived growth factor (PDGF), and parathyroid hormone-related protein (PTHrp), or combinations thereof.

12. The apparatus of claim 1 , wherein the stem cell is a hair follicle cell.

13. The apparatus of claim 12 , wherein the scanner is configured to rotate.

14. The apparatus of claim 12 , wherein the scanner comprises one or more galvanometer scanners.

15. The apparatus of claim 1 , wherein the optical beam is emitted by a laser.

16. The apparatus of claim 15 , wherein the laser is a CO 2 laser with a wavelength of about 10.6 μm.

17. The apparatus of claim 1 , further comprising a vacuum that removes debris that is removed from the skin during creation of the voids.

18. The apparatus of claim 1 , further comprising a system that creates a positive pressure in a chamber containing the composition.

19. The apparatus of claim 1 , wherein the voids are elongated.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
MERGER Recorded May 14, 2021
From: RELIANT TECHNOLOGIES, LLC
To: SOLTA MEDICAL, INC.
Reel/Frame 056244/0936 →
MERGER Recorded May 12, 2021
From: RELIANT TECHNOLOGIES, INC.
To: RELIANT TECHNOLOGIES, LLC
Reel/Frame 056218/0067 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →